Market revenue in 2023 | USD 25,642.9 million |
Market revenue in 2030 | USD 81,627.0 million |
Growth rate | 18% (CAGR from 2023 to 2030) |
Largest segment | Health |
Fastest growing segment | Bioinformatics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Health, Food & Agriculture, Natural reseources & Environment, Industrial Processing, Bioinformatics, Others Applications |
Key market players worldwide | AstraZeneca PLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Sanofi SA, Biogen Inc, Abbott Laboratories, Pfizer Inc, Amgen Inc, Novo Nordisk A/S ADR, Merck KGaA, Johnson & Johnson, Novartis AG ADR, Roche Holding AG, Lonza Group Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biotechnology market will help companies and investors design strategic landscapes.
Health was the largest segment with a revenue share of 44.66% in 2023. Horizon Databook has segmented the South Korea biotechnology market based on health, food & agriculture, natural reseources & environment, industrial processing, bioinformatics, others applications covering the revenue growth of each sub-segment from 2018 to 2030.
Over the past few years, biotechnology industry in South Korea has undergone several changes, leading to significant growth of the market. Biologics market is expected to be the fastest growing market in the country owing to flexible manufacturing facilities using disposables, new-cell culture techniques, fast track GMP facilities, and attempts for continuous manufacturing.
This expanding biologics industry is expected to positively impact the growth of biotechnology market in South Korea. Furthermore, the government has established a systematic government support plan to boost biopharmaceutical industry in the country.
Similarly, in summer 2019, a five-year plan for biotech-related R&D and commercialization was launched by South Korean government. In addition to government investments, private and public biotechnology companies would jointly invest USD 9.03 billion by 2023.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea biotechnology market , including forecasts for subscribers. This country databook contains high-level insights into South Korea biotechnology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account